Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and-or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Madrigal Pharmaceuticals, Inc. Corporate Site
Contact Us

Search for:

MASH
Educational Resources
Clinical Trials
Publications
Request Medical Information
Submit an Educational Grant Request
Investigator-Initiated Studies

MASH
Educational Resources
Clinical Trials
Publications
Request Medical Information
Submit an Educational Grant Request
Investigator-Initiated Studies
Contact Us

Effect of Resmetirom or Placebo in NASH Fibrosis Patients With <5% or ≥5% Weight Loss and-or on Baseline GLP-1 Therapy in the MAESTRO-NASH 52-Week Serial Liver Biopsy Study

Oral Presentation

File size: 1.02 MB

Created: 26-11-2024

Updated: 26-11-2024

Download Preview

Resmetirom is currently approved in the United States and by the European Union.

Terms of Use
Privacy
Cookies
U.S. Consumer Health Privacy
Manage Cookie Preferences
Your Privacy Choices

Page load link

This content is intended for your personal educational use only. Please do not download or distribute further. No further reproduction or distribution is permitted without permission from Madrigal.

By clicking below, you acknowledge and certify that you are a Healthcare Professional.

Yes, I am a U.S. Healthcare Professional

No, I am not a U.S. Healthcare Professional

If applying for an Educational Grant, click here:

I am applying for an educational grant

If applying for an Investigator-Initiated Grant, click here:

I am applying for an Investigator-Initiated grant

Go to Top